摘要
Abstract
Objective:To evaluate the incidence of adverse events and the recent curative effects on pegaspargase-asparaginase (PEG-ASP).Methods:From June 2014 to January 2016,48 children with acute lymphoblastic leukemia (ALL)in our hospital were divided into 3 groups (Group A:10 patients with PEG-ASP,Group B:25 patients with L-ASP,Group C:13 patients with L-ASP +PEG-ASP),and their curative effects and adverse reactions were observed.Results:(1 )In 48 children with ALL,34 cases(70.8%)were complete remission,8 cases(16.7%)relapsed,6 cases(12.5%)died;(2)The difference of the allergic reaction in three groups was statistically significant (P <0.05),other reactions as:Ⅲ-Ⅳ serious adverse reactions,digestive tract reaction,abnormal liver function, blood glucose and blood coagulation dysfunction were not statistical different(P >0.05).Conclusion:PEG-ASP can be used as a treat-ment for children with ALL,the incidence of allergic reactions is low,and close monitoring of adverse reactions during treatment index can increase the drug safety.关键词
培门冬酶/药物治疗/急性淋巴细胞白血病/儿童Key words
Pegaspargase-asparaginase (PEG-ASP )/Drug treatment/Acute lymphoblastic leukemia (ALL)/Children分类
医药卫生
